FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2901849740> ?p ?o ?g. }

• W2901849740 endingPage "962" @default.
• W2901849740 startingPage "955" @default.
• W2901849740 abstract "Controversy exists regarding the safety of agents that systemically inhibit epidermal growth factor receptor (EGFRi) in oncologic patients in terms of toxicity to the ocular surface. We performed a prospective clinical study comparing the ocular surface toxicity of systemic EGFRi between a case and a control group. Patients with lung or colon cancer were divided in two groups: 25 patients treated with systemic EGFRi and 25 control patients without EGFRi treatment. Patients in both groups were chemotherapy naive. Four visits were scheduled in a one year period comparing signs and symptoms in terms of symptom questionnaires (SIDEQ, OSDI and AVS), corneal fluorescein staining (Oxford test), tear production (Schirmer's test) and a quantitative evaluation of conjunctival chemosis and hyperemia. Basal epithelial cell density (CEBD) and corneal subepithelial nerve fiber density (CNFD) were measured and compared using confocal microscopy (Heidelberg Engineering, Germany). The differences in each variable were compared with the analysis of variance (ANOVA). A P value < 0.05 was considered significant for all comparisons. No statistically significant differences were found between patients under EGFRi treatment and the age-matched controls in the variables analyzed. When cases and controls were evaluated separately, the case group showed a significantly worse progression of signs (chemosis score, CFS, Schirmer's) as well as in terms of CEBD and CNFD (all P < 0.05). Systemic EGFRi may increase dry eye signs as well as decrease CEBD and CNFD. This study may help us to understand the true toxicity of EGFRi to the ocular surface. Il existe une inquiétude par rapport à la sécurité des médicaments inhibiteurs du récepteur du facteur de croissance épidermique par voie générale (EGFRi) en ce qui concerne la toxicité de la surface oculaire. Une étude prospective a été realisé pour évaluer cette toxicité. Des patients atteints d’un cancer de poumon ou côlon sous chimiothérapie de première intention ont été divisés en 2 groupes. Un premier groupe de 25 patients traités avec des EGFRi et 25 contrôles sans ce traitement. Un suivi d’un an a été réalisé avec 4 rendez-vous comparant des signes et des symptômes. On a utilisé les questionnaires SIDEQ, OSDI et VAS, le test d’Oxford, le test de Schirmer et une évaluation quantitative de chémosis et d’hyperémie conjonctivale. Avec la microscopie confocale (Heidelberg Engineering, Allemagne) on acomparé la densité basale cellulaire épitheliale cornéenne moyenne (CEBD) et la densité nerveuse sous-épithéliale (CNFD). Les différences ont été comparés avec l’analyse de la variance (ANOVA). Une p < 0,05 a été considérée significative pour les comparaisons. On n’a pas trouvé des différences significatives dans les variables analysées. Quand on a évalué les groupes séparément, les cas montrent une évolution moins favorable par rapportaux signes (chemosis, Oxford's et Schirmer) et au niveau de la CEBD et la CNFD (p < 0,05). Les EGFRi peuvent augmenter les signes de sécheresse oculaire et réduire la CEBD et la CNFD. Cet étude nous aide à éclaircir la toxicité de ces inhibiteurs au regard de la surface oculaire." @default.
• W2901849740 created "2018-11-29" @default.
• W2901849740 creator A5007254116 @default.
• W2901849740 creator A5018761595 @default.
• W2901849740 creator A5019386195 @default.
• W2901849740 creator A5051560979 @default.
• W2901849740 creator A5062594022 @default.
• W2901849740 creator A5074560237 @default.
• W2901849740 creator A5087391532 @default.
• W2901849740 date "2018-12-01" @default.
• W2901849740 modified "2023-10-18" @default.
• W2901849740 title "Ocular surface adverse events of systemic epidermal growth factor receptor inhibitors (EGFRi): A prospective trial" @default.
• W2901849740 cites W1596261235 @default.
• W2901849740 cites W1963969809 @default.
• W2901849740 cites W1966934424 @default.
• W2901849740 cites W1982794477 @default.
• W2901849740 cites W1992660677 @default.
• W2901849740 cites W1992913621 @default.
• W2901849740 cites W1999241959 @default.
• W2901849740 cites W2002972638 @default.
• W2901849740 cites W2012125135 @default.
• W2901849740 cites W2030153375 @default.
• W2901849740 cites W2038086562 @default.
• W2901849740 cites W2042278676 @default.
• W2901849740 cites W2052938321 @default.
• W2901849740 cites W2057270041 @default.
• W2901849740 cites W2061624939 @default.
• W2901849740 cites W2065645867 @default.
• W2901849740 cites W2066582161 @default.
• W2901849740 cites W2069015893 @default.
• W2901849740 cites W2069915761 @default.
• W2901849740 cites W2096287391 @default.
• W2901849740 cites W2098152212 @default.
• W2901849740 cites W2129579482 @default.
• W2901849740 cites W2164730961 @default.
• W2901849740 cites W2760047982 @default.
• W2901849740 cites W4237471076 @default.
• W2901849740 cites W2035047470 @default.
• W2901849740 cites W2747423926 @default.
• W2901849740 doi "https://doi.org/10.1016/j.jfo.2018.07.005" @default.
• W2901849740 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30473235" @default.
• W2901849740 hasPublicationYear "2018" @default.
• W2901849740 type Work @default.
• W2901849740 sameAs 2901849740 @default.
• W2901849740 citedByCount "4" @default.
• W2901849740 countsByYear W29018497402020 @default.
• W2901849740 countsByYear W29018497402021 @default.
• W2901849740 countsByYear W29018497402023 @default.
• W2901849740 crossrefType "journal-article" @default.
• W2901849740 hasAuthorship W2901849740A5007254116 @default.
• W2901849740 hasAuthorship W2901849740A5018761595 @default.
• W2901849740 hasAuthorship W2901849740A5019386195 @default.
• W2901849740 hasAuthorship W2901849740A5051560979 @default.
• W2901849740 hasAuthorship W2901849740A5062594022 @default.
• W2901849740 hasAuthorship W2901849740A5074560237 @default.
• W2901849740 hasAuthorship W2901849740A5087391532 @default.
• W2901849740 hasConcept C118487528 @default.
• W2901849740 hasConcept C121608353 @default.
• W2901849740 hasConcept C126322002 @default.
• W2901849740 hasConcept C16005928 @default.
• W2901849740 hasConcept C188816634 @default.
• W2901849740 hasConcept C197934379 @default.
• W2901849740 hasConcept C2779438470 @default.
• W2901849740 hasConcept C2779714575 @default.
• W2901849740 hasConcept C71924100 @default.
• W2901849740 hasConceptScore W2901849740C118487528 @default.
• W2901849740 hasConceptScore W2901849740C121608353 @default.
• W2901849740 hasConceptScore W2901849740C126322002 @default.
• W2901849740 hasConceptScore W2901849740C16005928 @default.
• W2901849740 hasConceptScore W2901849740C188816634 @default.
• W2901849740 hasConceptScore W2901849740C197934379 @default.
• W2901849740 hasConceptScore W2901849740C2779438470 @default.
• W2901849740 hasConceptScore W2901849740C2779714575 @default.
• W2901849740 hasConceptScore W2901849740C71924100 @default.
• W2901849740 hasIssue "10" @default.
• W2901849740 hasLocation W29018497401 @default.
• W2901849740 hasLocation W29018497402 @default.
• W2901849740 hasOpenAccess W2901849740 @default.
• W2901849740 hasPrimaryLocation W29018497401 @default.
• W2901849740 hasRelatedWork W2092900223 @default.
• W2901849740 hasRelatedWork W2135329844 @default.
• W2901849740 hasRelatedWork W2295722933 @default.
• W2901849740 hasRelatedWork W2365364931 @default.
• W2901849740 hasRelatedWork W2374781999 @default.
• W2901849740 hasRelatedWork W2418638721 @default.
• W2901849740 hasRelatedWork W2527805684 @default.
• W2901849740 hasRelatedWork W2738981461 @default.
• W2901849740 hasRelatedWork W4234833016 @default.
• W2901849740 hasRelatedWork W4297184974 @default.
• W2901849740 hasVolume "41" @default.
• W2901849740 isParatext "false" @default.
• W2901849740 isRetracted "false" @default.
• W2901849740 magId "2901849740" @default.
• W2901849740 workType "article" @default.